The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Nardil
Synonyms :
Class :
Antidepressants and antianxiety drugs; MAO inhibitors
Brand Name :
Nardil
Synonyms :
Class :
Antidepressants and antianxiety drugs; MAO inhibitors
Dosage forms & Strengths:Â
Adult:Â
Tablet:Â
15 mgÂ
Safety & efficacy is not seen in pediatrics Â
Concurrent use within 14 days after pholcodine treatment may lead to serotonin syndrome
Concurrent use within 14 days after pholcodine treatment may lead to serotonin syndrome
Concurrent use within 14 days after pholcodine treatment may lead to serotonin syndrome
Concurrent use within 14 days after pholcodine treatment may lead to serotonin syndrome
may increase the serotonergic effects
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may increase the efficacy of each other when combined
there is a danger of serotonin syndrome; thus, avoid using this product in patients receiving MAOIs or within two weeks or after stopping MAOI treatment
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
it increases the effect of hypertension of alpha 1-agonists
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased hypertensive effect when combined with alpha1-agonists
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased serotonergic effect when combined with selective serotonin reuptake inhibitors
may have an increased serotonergic effect when combined with selective serotonin reuptake inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
it increases the toxicity of diphenoxylate through an unknown mechanism
it increases the effect of hypertension of bupropion
it may increase the effect of serotonergic agents
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of SSRIs
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of SSRIs
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may increase the hypertension effect of alfa one agonist
may increase the adverse effect of sympathomimetic drugs
may increase the toxic effects of CNS depressants
may increase the serotonergic effect of tricyclic antidepressants
buprenorphine increases the toxicity of MAO inhibitors
acrivastine and pseudoephedrineÂ
may increase the hypertensive effects of alpha/beta agonists
may decrease the hypertensive effect of amphetamines
methyldopa/hydrochlorothiazideÂ
may increase the toxic effect of methyldopa
may have an increased adverse effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increasingly adverse effect when combined with codeine
may increase the toxic effect of carbinoxamine
buspirone increases the serotonergic effect of MAO inhibitors
may increase the serotonergic effect
promethazine/dextromethorphanÂ
may increase the serotonergic effect of Dextromethorphan
may have an increasingly adverse effect when combined with isometheptene
may increase the adverse effect of Buprenorphine
buprenorphine,long-acting injectionÂ
may increase the adverse effect of Buprenorphine
acetaminophen/doxylamine/dextromethorphanÂ
may increase the serotonergic effect of dextromethorphan
metoclopramide increases the effect of hypertension of MAO inhibitors
viloxazine: they may enhance the hypertensive effect of monoamine oxidase inhibitors
may increase the hypertensive effect of Monoamine Oxidase Inhibitors
may have an increased risk of serotonin syndrome when combined with kratom
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
they increase the toxicity of bezafibrate
may have an increased hypertensive effect when combined with alpha1-agonists
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
it increases the toxicity of MAO inhibitors
it enhances the serotonergic effect of MAO inhibitors
MAO inhibitors increase the toxic or adverse effects of hydromorphone
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
apraclonidine: it may increase the toxic effect of monoamine oxidase inhibitors A
apraclonidine: it may increase the toxic effect of monoamine oxidase inhibitors
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with blood glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood glucose lowering effects
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
it increases the effect of serotonergic agents
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increased hypoglycemic effect when combined with hypoglycemic agents
It may enhance the risk of adverse effects when combined with monoamine oxidase
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increased serotonergic effect when combined with tricyclic antidepressants
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
It may lead to sedation, respiratory depression, and coma
It may lead to sedation, respiratory depression, and coma
It may lead to sedation, respiratory depression, and coma
it may increase the toxic or adverse effects of hydromorphone
it may increase the effect of serotonergic agents
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the toxic effect
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
linezolid may enhance the serotonergic effect of MAO inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the hypoglycemic effect of blood glucose-lowering agents
may have an increased hypertensive effect when combined with norepinephrine
It may increase the hypertensive effect when combined with epinephrine (Systemic)
empagliflozin and linagliptinÂ
may increase the hypoglycaemic effect with blood glucose lowering agents
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the adverse effect when combined
may enhance the serum concentration when combined
mazindol increases the effect of hypertension when taken with MAO inhibitors
MAO inhibitors increase the anticholinergic action of clemastine
MAO inhibitors increase the anticholinergic action of doxylamine
it increases the effect of hypertension on MAO inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when MAOIs used in combination
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
MAO inhibitors increase the toxic or adverse effects of reserpine
MAO inhibitors increase the serotonergic effect of lithium
MAO inhibitors increase the toxic or adverse effects of hydrocodone
benzhydrocodone/acetaminophenÂ
it increases the serotonergic effect of MAO inhibitors
Frequency undefined:Â
Orthostatic hypotensionÂ
AstheniaÂ
DizzinessÂ
HeadacheÂ
DrowsinessÂ
FatigueÂ
HyperreflexiaÂ
Sleep disturbanceÂ
SomnolenceÂ
WeaknessÂ
TremorÂ
Dry mouthÂ
Weight gainÂ
Phenelzine is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
No data available for utilization in pregnant womenÂ
Breastfeeding warnings:Â Â
Drug distribution in breast milk is unknown, so use the drug cautiously during lactation.Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name:Â phenelzineÂ
Pronounced: phen-el-zineÂ
Why do we use phenelzine?Â
Phenelzine lies under MAO inhibitors and treats depression.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
